Table 3.
Association between the severity of NAFLD at baseline and risk of developing worsening of glycaemic control at follow-up in postmenopausal women with type 2 diabetes.
| Logistic Regression Models | Odds Ratios (95% CI) | p-Value |
|---|---|---|
| Unadjusted model | ||
| NAFLD and clinically significant fibrosis § | 4.66 (1.07–20.3) | 0.041 |
| Adjusted model 1 | ||
| NAFLD and clinically significant fibrosis | 4.72 (1.07–20.7) | 0.040 |
| Age (years) | 0.98 (0.91–1.06) | 0.678 |
| BMI (kg/m2) | 0.99 (0.88–1.12) | 0.866 |
| Adjusted model 2 | ||
| NAFLD and clinically significant fibrosis | 4.70 (1.07–20.8) | 0.041 |
| Age (years) | 0.99 (0.91–1.08) | 0.724 |
| BMI (kg/m2) | 0.98 (0.87–1.11) | 0.827 |
| GLP-1 receptor agonist use | 1.42 (0.21–10.1) | 0.724 |
| Adjusted model 3 | ||
| NAFLD and clinically significant fibrosis | 4.99 (1.14–21.9) | 0.033 |
| Age (years) | 0.96 (0.88–1.05) | 0.376 |
| BMI (kg/m2) | 0.99 (0.87–1.12) | 0.942 |
| SGLT-2 inhibitor use | 0.12 (0.10–3.07) | 0.198 |
| Adjusted model 4 | ||
| NAFLD and clinically significant fibrosis | 4.11 (1.03–16.4) | 0.045 |
| Age (years) | 0.99 (0.92–1.06) | 0.744 |
| BMI (kg/m2) | 1.00 (0.89–1.11) | 0.958 |
| Pioglitazone use | 1.21 (0.45–33.2) | 0.907 |
Sample size, n = 61. Data are expressed as odds ratio and 95% confidence intervals (CI) as tested by logistic regression analyses. The presence of worsening of glycaemic control at follow-up (arbitrarily defined as HbA1c increase ≥ 0.5%) was the dependent variable in these logistic regression models. Covariates included in these regression models were recorded at baseline. § Clinically significant fibrosis was defined by LSM ≥ 7 kPa on Fibroscan®.